cygenics

A Healthcare Company Focused On Tissue & Cord Blood Banking

Disclaimer

The material contained in this presentation must be considered as general background information on Cygenics Ltd. This presentation does not contain any earning guidance. The information presented is in summary form and where indicated figures used are unaudited. The information contained in this presentation is subject to risks and uncertainties that may cause actual results to differ materially from those indicated. This information should not be relied upon or seen as advice as to investors. Investors should obtain independent professional advice.



Corporate snapshot

KEY FINANCIALS

MAJOR SHAREHOLDERS

ASX Code:	CYN	Steven Fang (Founder and CEO)	12.8%
Share Price:	\$0.30	National Nominees (Co-founders)	8.2%
Shares on Issue:	68.0m	NEFCO Nominees (IPO Investors)	7.5%
Market Cap:	\$20.4m	Tar Choon Aw (Co-founder)	5.5%
Revenue: (full year FY06)	\$8.27m	CitiCorp Nominees (Investors)	5.3%
Cash:	\$3.92m	QIC (IPO Investor)	4.9%
(Sept 2006)		Mandalay Capital (Chairman)	4.4%



Business strategy



Tissue & Cord Blood Banking





Healthcare company focused on tissue and cord blood banking



Recent announcements



- Chinese blood bank collaboration
 - First step towards business activities in China, including cord blood banking

India market expansion

- Establishing alliances with key hospitals and leading obstetricians
- New cord blood processing and storage facility to be established in Q2 2007

Indonesian market expansion

- Leading Indonesian pharma company takes 49% stake in CordLife Indonesia
- New cord blood processing and storage facility to be established in early 2007

Focus on cord blood banking

 Focus on revenue generating tissue and cord blood banking businesses

Focus on revenue generating tissue and cord blood banking businesses



Tissue and cord blood banking



Nature of business

- Collection, processing and storage of Cord Blood Stem Cells
 - Used in transplant (75 cancers & diseases)
 - Moving to therapy (heart, diabetes, stroke)

Revenue & Margins

- Upfront **\$1,300**, gross margin **50%**
- Annuity **\$190**, locked in for **18 years**

What are Stem Cells ?

Simple business model



Market Dynamics



- Existing market
 - North Asia 23,000 cord blood units banked privately

• Market growth drivers

- Clinical acceptance
- Growing number of cord blood stem cell transplants
- Consumer awareness

People want to use the service

- Improve future healthcare outcome & reduce costs
- Therapy moving into common diseases (heart, diabetes, stroke)

Increasing demand for tissue and cord blood banking




Projected Market Growth

Financial Year	FY05	FY06	FY07	FY08
Market	Singapore	Singapore	Singapore	Singapore
	SE Asia	SE Asia	SE Asia	SE Asia
		Australia	Australia	Australia
			India	India
			Indonesia	Indonesia
				China
Accessible Market	8,500	12,600	25,000	286,000
Internal estimate based on the number of births, adjusted for disposable income and market uptake data				
Client Numbers	3,000	6,000	12,000	26,000
Actual and Projected				
Cord Blood Banking Revenue	\$1.6m	\$3.6m		
Including Annuity of	\$95,000	\$300,000	\$750,000	

Strong projected regional growth



Company Revenue Growth



*IPO proforma

Significant revenue growth



Competitive Landscape



Leadership position

	Cygenics	Competitors
Scale	Regional	Local
Brand	Regional & Local	Local
Operations	Regional & Local	Local
Quality Standards	International & Local	Local
Economies	Scale	Minimal

Minimal competition



Company value drivers



- Increasing regional presence
 - Existing markets: Australia, Singapore, Hong Kong, Indonesia, Thailand
 - Growth markets: India, China, Indonesia
- Focus on organic growth
- Driving inorganic growth through M&A and alliances
- Co-development/out-licensing opportunities with technology portfolio

Largest network of private cord blood banks in the region




Technology Investment Portfolio

Investee Company	Nature of Business	Current Holdings	Target Holdings
Cytomatrix	RegenImmune, T-cell production technology with ongoing grant projects PACRIMA (Europe), DCPrime (Malaysia) and BioDeakin ¹ (Australia)	100%	20%
	TranStem, Adult Stem Cell expansion technology with ongoing grant projects BioDeakin ¹ (Australia)	100%	20%
Cytovations	Bioreactor / Biologics technology with ongoing grant projects BioDeakin ¹ (Australia)	100%	20%
CLS	Medical referrals business	100%	20%
Pharmacell	Biologics cGMP manufacturing business	20%	20%
DNAPro	Product distribution and logistics business	19.7%	19.7%

Note 1 : Not yet awarded



A compelling investment opportunity



- High growth healthcare business
- The only regional cord blood banking company
- Scalable & proven business model
- Growing annuity revenue stream
- Technology investment portfolio upside



Contact Details

Steven Fang, CEO Mobile +61 (0)400 933 243 Email steven.fang@cygenics.com

Ian Brown, COO Mobile +61 (0)438 565 212 Email ian.brown@cygenics.com

Cygenics Limited Level 2, 405 Lt Bourke St Melbourne, Victoria 3000, Australia Telephone +61 (0)3 9642 5580 Facsimile +61 (0)3 9642 5581 Web www.cygenics.com